Andrzej P Kudelka
Overview
Explore the profile of Andrzej P Kudelka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
171
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hu Z, Schuster J, Kudelka A, Huston T
J Cutan Med Surg
. 2015 Dec;
20(3):255-8.
PMID: 26676953
Background: Merkel cell carcinoma (MCC) is a rare, highly aggressive cutaneous neoplasm, with a propensity for recurrence and metastasis. Very few cases of metastases to the gastrointestinal tract have been...
2.
Verschraegen C, Skubitz K, Daud A, Kudelka A, Rabinowitz I, Allievi C, et al.
Cancer Chemother Pharmacol
. 2008 Aug;
63(5):903-10.
PMID: 18682950
Purpose: Determine the toxicity, maximum tolerated dose (MTD), and pharmacokinetics of paclitaxel poliglumex (PPX; CT-2103) in combination with cisplatin administered every 3 weeks. Patients And Methods: Forty-three patients with advanced...
3.
Kraeher A, Eledrisi M, Lieberman S, Kudelka A
Endocr Pract
. 2006 Apr;
11(6):412.
PMID: 16638731
No abstract available.
4.
Hu W, Wu W, Verschraegen C, Chen L, Mao L, Yeung S, et al.
Proteomics
. 2003 Nov;
3(10):1904-11.
PMID: 14625852
Farnesyl transferase inhibitors (FTIs) are novel antitumor drugs with clinical activity. FTIs inhibit cell growth not only by preventing direct Ras farnesylation but also through a Ras-independent pathway. Proteomics has...
5.
Cohen L, Baile W, Henninger E, Agarwal S, Kudelka A, Lenzi R, et al.
J Behav Med
. 2003 Nov;
26(5):459-71.
PMID: 14593853
We examined the acute stress response associated with having to deliver either bad or good medical news using a simulated physician-patient scenario. Twenty-five healthy medical students were randomly assigned to...
6.
Verschraegen C, Kudelka A, Hu W, Vincent M, Kavanagh J, Loyer E, et al.
Cancer Chemother Pharmacol
. 2003 Oct;
53(1):1-7.
PMID: 14586557
Background: DX-8951f is a water-soluble camptothecin derivative with greater in vivo and in vitro activity than topotecan or irinotecan. The objectives of this phase II study were to determine the...
7.
Melichar B, Lenzi R, Rosenblum M, Kudelka A, Kavanagh J, Melicharova K, et al.
J Immunother
. 2003 Jun;
26(3):270-6.
PMID: 12806280
Activated monocytes-macrophages may be associated with antitumor activity, and activation of these cells by certain cytokines, primarily interferon gamma (IFN-gamma), can be indicated by alterations in the concentrations of neopterin,...
8.
Verschraegen C, Hu W, Du Y, Mendoza J, Early J, Deavers M, et al.
Clin Cancer Res
. 2003 Feb;
9(2):845-52.
PMID: 12576458
Purpose: The purpose of this study was to characterize cell cultures and xenografts derived from patients with ovarian cancer. Experimental Design: Ninety specimens from 67 patients were plated in RPMI...
9.
Lenzi R, Rosenblum M, Verschraegen C, Kudelka A, Kavanagh J, Hicks M, et al.
Clin Cancer Res
. 2002 Dec;
8(12):3686-95.
PMID: 12473577
Purpose: The purpose is to determine dose-limiting toxicity, pharmacokinetics,pharmacodynamics, and immunobiology after i.p. injections of recombinant human IL-12 (rhIL-12). Experimental Design: rhIL-12 was administered to 29 previously treated patients with...
10.
Le Blanc M, Russo J, Kudelka A, Smith J
Pharmacol Res
. 2002 Nov;
46(6):551-5.
PMID: 12457630
Gossypol, a cottonseed extract, has been shown to have antiproliferative activity in a variety of cancer cell lines. The objective of this study was to determine the inhibitory effects of...